Table 2 Bivariate logistic regression analysis for VTE risk assessment.
OR | 95% CI | p value | ||
|---|---|---|---|---|
Pandemic waves | ||||
Other waves | – | – | – | – |
First wave | 1.17 | 0.86 | 1.63 | 0.30 |
Second wave | 1.37 | 0.96 | 1.98 | 0.09 |
Age > 70 years | 0.94 | 0.76 | 1.08 | 0.28 |
Sex (female) | 0.80 | 0.58 | 0.84 | < 0.01 |
Arterial hypertension | 1.02 | 0.82 | 1.28 | 0.84 |
Chronic atrial fibrillation | 0.44 | 0.29 | 0.65 | < 0.01 |
Cancer | 1.37 | 0.97 | 1.89 | 0.06 |
Dyspnea | 1.59 | 1.32 | 1.94 | < 0.01 |
Pulmonary infiltrates | 1.10 | 0.84 | 1.47 | 0.51 |
ARDS | 2.02 | 1.69 | 2.41 | < 0.01 |
Heart rate > 100 bpm | 1.44 | 1.18 | 1.75 | < 0.01 |
SPB < 90 mmHg | 1.06 | 0.59 | 1.75 | 0.83 |
PaO2/FiO2 ratio < 300 | 1.79 | 1.43 | 2.27 | < 0.01 |
Intensive care unit admission | 3.87 | 3.16 | 4.71 | < 0.01 |
Lymphocyte < 800/µL | 0.99 | 0.83 | 1.19 | 0.93 |
D-dimer > 1000 ng/mL | 4.03 | 3.35 | 4.86 | < 0.01 |
CRP > 100 mg/L | 1.43 | 1.20 | 1.71 | < 0.01 |
Creatinine > 1.5 mg/dL | 1.01 | 0.77 | 1.30 | 0.95 |
Lopinavir/ritonavir | 0.83 | 0.69 | 1.01 | 0.06 |
Remdesivir | 1.17 | 0.82 | 1.61 | 0.37 |
Hydroxychloroquine | 1.06 | 0.84 | 1.34 | 0.61 |
Beta interferon | 1.48 | 1.06 | 2.01 | 0.02 |
Macrolides | 0.76 | 0.63 | 0.90 | < 0.01 |
Beta-lactams | 1.54 | 1.26 | 1.89 | < 0.01 |
Corticosteroids | 1.98 | 1.63 | 2.41 | < 0.01 |
Anakinra | 3.28 | 1.66 | 5.84 | < 0.01 |
Tocilizumab | 2.95 | 2.41 | 3.60 | < 0.01 |
Prophylactic LMWH | 1.17 | 0.65 | 2.33 | 0.63 |
